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Background & aims: Muscle wasting in cancer negatively affects physical function and quality of life. This
study investigates amino acid metabolism and the association with muscle mass and function in patients
with cancer.
Methods: In 16 patients with advanced cancer undergoing chemotherapy and 16 healthy controls, we
administered an intravenous pulse and prime of stable amino acid tracers. We took blood samples to
measure the Rate of appearance (Ra), whole body production (WBP), clearance (Cl), and post absorptive
whole body net protein breakdown (WBnetPB). Plasma amino acid concentrations and enrichments
were analysed by LC-MS/MS. We assessed muscle mass, handgrip/leg/respiratory muscle strength and
reported physical activity, quality of life, and physical function.
Results: Muscle strength was lower in cancer patients than in healthy controls. Total and limb muscle
mass, reported physical activity and WBnetPB were comparable. WBP and Cl of tau-methylhistidine,
leucine, glutamine and taurine were higher in cancer patients as well as glycine Cl. Amino acid meta-
bolism was correlated with low muscle mass, strength, physical function and quality of life.
Conclusions: Myofibrillar protein breakdown and production of amino acids involved in muscle
contractility are up regulated in patients with cancer undergoing chemotherapy and related to muscle
weakness and reduced physical outcomes.
© 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
An important indicator of health, well-being and treatment
outcome in patients with cancer is the amount of muscle mass and
function in the body. A relatively low amount of muscle mass has
been observed in 20%e70% of people with cancer [1] and is asso-
ciated with physical impairment, impaired quality of life [2],
treatment toxicity, and a shorter survival [3,4]. A loss of muscle
mass is called ‘sarcopenia’ and is usually associated with ageing [1].
Muscle loss associated with chronic diseases, including cancer, isngelen).
for Clinical Nutrition and Metabol
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ired physical function, Clinicaoften referred to as ‘secondary sarcopenia’ [1]. Besides secondary
sarcopenia, skeletal muscle weakness is frequently observed in
stable patients with advanced cancer [5,6] and during or after anti-
cancer treatment [6,7]. Previous studies showed that infusion of the
chemotherapy drug doxorubicin in an animal model caused per-
manent muscle necrosis, loss of muscle mass, altered myofilament
structure, and depressed force [8], while in patients with lym-
phoma, leukaemia and breast cancer doxorubicin treatment
resulted in muscle weakness and fatigue [9].
Over the years, many studies have focused on the metabolic
disturbances underlying muscle wasting and the role of the
enhanced chronic systemic inflammatory response in cancer [10,11].
For instance, the presence of a tumour is related to metabolicism. All rights reserved.
rnover and myofibrillar protein breakdown in advanced cancer are
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B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx2alterations initiated by factors such as increased adrenal activity and
glucocorticoid levels, muscle-specific activation of nuclear factor
kappa B (NF-kB), activation of the ubiquitin-dependent proteasome
pathway, release of pro-inflammatory cytokines as a result of sys-
temic inflammation, and diminished glucose tolerance. These factors
increase basal metabolic rate, inhibit adipocyte and skeletal myocyte
differentiation, and reduce food intake [10]. In addition, chemo-
therapy and radiotherapy can further reduce food intake and alter
metabolism by causing nausea, vomiting, dysgeusia and fatigue,
further contributing to weight loss and muscle wasting [12,13].
Altered whole body rate of appearance of amino acids has been
reported in patients with advanced cancer [14,15]. In addition,
abnormal plasma free amino acid profiles that differ among cancer
stages, tumour types and degrees of weight loss have been reported
[16,17]. Studies examining muscle metabolism in patients with
cancer found inconsistent results as skeletal muscle protein frac-
tional synthesis rate was found to be unchanged or reduced in
patients with cancer [10,18]. A recent study examining muscle
myofibrillar protein synthesis found comparable values between
healthy participants and weight-losing patients with gastrointes-
tinal cancer [19], suggesting that muscle wasting is likely more
related to increased muscle protein breakdown [18]. We have
recently shown that muscle weakness in cancer cannot be fully
explained by the presence of muscle loss alone: with the upcoming
rates of overweight and obesity, preserved values for muscle mass
and presence of a high body fat are more common in patients with
cancer [20]. Disturbances in protein metabolism are observed in
many cancer types, even when cachexia or weight loss is absent
[11,21]. Also, chemotherapeutic agents like methotrexate (MTX)
and 5-fluorouracil (5-FU) decrease nitrogen balance in tumour-
bearing rats [22]. In children with acute leukaemia receiving MTX
treatment, increased rates of whole-body protein turnover and
synthesis were observed [23]. Thus there are clear changes in
whole body protein metabolism and muscle metabolism in cancer
patients undergoing chemotherapy. So far, it was unclear whether
these changes relate to the metabolism of other amino acids.
In the present study, we used a targetedmetabolic flux approach
to examine the (protein and amino acid) metabolic characteristics
of a well-described heterogeneous group of advanced stage cancer
patients undergoing chemotherapy using a combined pulse and
primed-constant infusion of multiple stable isotopes. The effect of
cancer-induced altered metabolism on muscle mass and contrac-
tility was evaluated by measuring amino acids markers for protein
breakdown including phenylalanine, taurine, methylhistidine,
glutamine, taurine and glycine.
2. Materials and methods
2.1. Subjects
The study population included 16 patients with advanced can-
cer and 16 gender- and age-matched healthy subjects from the
MEDIT trial (MEtabolism of Disease with Isotope Tracers) (Table 2)
[24]. Recruitment of patients with cancer took place through
oncologist referral from the Scott & White Hematology/Oncology
Clinic, St Joseph Regional Cancer Center, Aggieland Cancer Treat-
ment Center and MD Anderson Cancer Center (College Station/
Bryan/Houston, TX, USA). All patients with cancer had solid tu-
mours and were scheduled for chemotherapy or chemo-
radiotherapy, able to sign informed consent, and 18 years or older.
Control subjects were healthy males or females according to the
investigator's or appointed staff's judgment, 18 years or older, and
did not have a diagnosis of cancer. Cancer and healthy subjects with
previous pre-existent metabolic or renal diseases or untreated
metabolic diseases including liver or renal disease were excludedPlease cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinicafrom participation. The study was performed in accordance with
the Declaration of Helsinki.Written informed consent was obtained
from all subjects and the study was approved by the Institutional
Review Board of Texas A&M University (reference number: 2012-
0504) and the study was registered in the Clinical Trial Registration
(reference number: NCT01871350). All subjects were studied at the
Clinical Research Unit of the Center for Translational Research on
Aging and Longevity, Texas A&M University. The study procedures
were identical in both groups and the study day lasted approxi-
mately 6 h (Supplementary Fig. 1).
2.2. Anthropometrics and body composition
Body weight and height were measured by a digital beam scale
and stadiometer, respectively.
Furthermore, whole body, trunk and extremity (arms and legs)
fat mass (FM) and fat-free mass (FFM) were obtained from all
subjects while in supine position by dual-energy X-ray absorpti-
ometry (DXA) (Hologic QDR 4500/Version 12.7.3.1 (Bedford, MA,
USA)). Anthropometric and body composition measures were
standardized for height (kg/m2), as suggested by VanItallie [25] to
obtain BMI, FFM index (FFMI), FM index (FMI) and appendicular
skeletal muscle index (ASMI).
2.3. Muscle function
Respiratory and skeletal muscle function was assessed in all
subjects. Maximal expiratory pressure (MEP) and maximal inspi-
ratory pressure (MIP) were assessed by determining the maximal
value of at least 3 reliable attempts using a hand-held mouth
pressure device (Micro Respiratory Pressure Meter (RPM) (Vernier,
Beaverton, OR)) [26].
Following pre-test stretching and warm-up, the peak leg force
during one leg reciprocal extensions (at 60/sec) and the peak
handgrip force that the subject was able to generate out of 3
reproducible repetitions, with 1 min of rest between each attempt,
were used as marker of leg strength and handgrip strength, using
Kincom isokinetic dynamometry (Isokinetic International, Chatta-
nooga, TN, USA) [27] and Vernier dynamometry (Vernier software
and Technology, Beaverton, OR, USA) respectively [28].
2.4. Stable isotope infusion by IV pulse or continuous infusion
In the early morning after an overnight fast, a peripheral line
was placed in a vein of the lower arm for stable tracer infusion and
in a superficial dorsal vein of the contralateral hand for blood
sampling. The hand was placed in a thermostatically controlled hot
box (internal temperature: 50 C), a technique to mimic direct
arterial sampling [29]. Two methods of stable amino acid tracers
were applied to investigate protein and amino acid kinetics on an
individual level: first, a pulse method by analysing the decay curves
of the tracer enrichments in plasma using (non)-compartmental
modelling. This enables measuring the WbRa of amino acids with
different pool sizes. The second method is a primed-constant
infusion of stable tracers of amino acids with careful priming to
obtain tracer steady state of PHE and TYR and measure whole body
protein synthesis and breakdown [24].
For the pulse method, two syringes of a cocktail of stable amino
acids (15e30 mL) tracers used to characterize muscle metabolism
(Cambridge Isotope Laboratories, Cambridge, UK 140 (Wolburn,
MA, USA)) [25] were administered intravenously after a venous
blood samplewas collected tomeasure baseline tracer enrichments
(Table 1) [25].
We report the isotope labels and concentrations of the amino
acids tau-methylhistidine (tau-MetHis), glycine (Gly), taurine (Tau)rnover and myofibrillar protein breakdown in advanced cancer are
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Table 1
Composition of the infused stable isotopes.
Time IV administration Stable isotopes Dose per kg body weight (mmol/kg ffm)
Baseline Pulse L-tau-Methylhistidine-[2H3] 0.061
L-Leucine-[2H3] 1.56
Glycine-[2H2] 9.37
L-Glutamine-[5-15N] 6.25
L-Taurine[1,2-13C2] 0.729
þ2 h Primed-constant infusion L-Phenylalanine-[ring-2H5] Prime: 75% of hourly infusion rate
Infusion: 0.167
L-Tyrosine-[13C9-15N] Prime: 75% of hourly infusion rate
Infusion: 0.0053
Table 2
General characteristics, body composition, muscle function, dietary intake and physical activity of healthy controls and patients with cancer at enrolment.
Mean (SEM), except when stated otherwise Healthy controls (n ¼ 16) Cancer patients (n ¼ 16) P-value Healthy vs. Cancer
Gender (m/f) e n 9/7 9/7 1.00
Age (y) 59.3 (4.0) 60.1 (4.2) 0.90
Weight (kg) 77.6 (3.1) 73.0 (3.9) 0.36
BMI (kg/m2) 26.7 (0.8) 26.8 (1.4) 0.95
BMI category
20e25 kg/m2 5 (31) 8 (50) 0.47
>25e30 kg/m2 7 (44) 4 (25)
>30 kg/m2 4 (25) 4 (25)
Body composition
FFM (kg) 53.0 (2.6) 48.6 (2.6) 0.23
FFM-index (kg/m2) 18.1 (0.6) 17.7 (0.6) 0.56
FFM-index extremities (kg/m2) 7.7 (0.3) 7.3 (0.3) 0.34
Appendicular Skeletal Muscle Index (ASMI) 7.3 (0.3) 6.9 (0.3) 0.30
Sarcopeniaa (n, %) 3 (19) 6 (38) 0.24
Android/gynoid ratio 1.0 (0.04) 1.0 (0.06) 0.26
Abdominal obesity (n, %) 11 (69) 10 (63) 0.34
Muscle function
Maximal inspiratory pressure (cm H2O) 115.8 (10.5) 72.2 (7.6) 0.009
Maximal expiratory pressure (cm H2O) 124.2 (9.8) 90.2 (10.2) 0.09
Handgrip strength (N) 291.6 (16.5) 235.9 (23.0) 0.06
Handgrip strength (N/kg FFM extremities) 13.1 (0.6) 11.6 (0.7) 0.11
Leg extension strength (N) 374.1 (36.1) 252.6 (29.5) 0.01
Leg extension strength (N/kg FFM extremities) 16.1 (1.0) 12.2 (1.0) 0.01
Leg flexion strength (N) 188.3 (17.9) 158.3 (16.2) 0.22
Leg flexion strength (N/kg FFM extremities) 8.4 (0.7) 7.8 (0.5) 0.48
Dietary intake and physical activity
Energy intake (kcal/d) 1949 (131) 1724 (214) 0.38
Protein intake (g/kg/d) 1.07 (0.05) 1.06 (0.17) 0.93
Physical activity level (PASE-questionnaire) 165.1 (20.7) 135.0 (25.1) 0.36
ASMI, appendicular skeletal muscle index; BMI, body mass index; FFM, fat free mass, PASE Physical Activity Scale for the Elderly.
Bold values represents P <0.05.
B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx 3and glutamine (Gln), known to play a role in muscle metabolism
(Table 1). In addition, 2 h after the pulse we started a primed
constant and continuous infusion of the stable tracers of phenyl-
alanine and tyrosine, lasting for 4 h.
Arterialized-venous blood was sampled at multiple time points
at t ¼ 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120 min after pulse
administration and 30, 60, 90 and 105 and 120 min after starting
the continuous infusion.
Blood samples were taken for analysis of the tracer enrichments
and concentrations of amino acids.2.5. Questionnaires
On the day of the study, habitual dietary intake was assessed by
24-h dietary recall, a retrospective method that consists of recall-
ing, describing and quantifying the intake of foods and beverages
consumed in the past 24 h. This information was used for coding
and analysed for energy and protein intake. Habitual physical ac-
tivity level was measured by the Physical Activity Scale for the
Elderly questionnaire (PASE) [30]. This questionnaire, intended for
use in an older adult population, has been validated to measurePlease cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinicaself-reported physical activity in lung cancer [31] and focuses on 3
types of activities: leisure time activities, household activities and
work-related activities.
In patients with cancer, the Karnofsky Performance Score was
used to assess functional status. The Karnofsky Performance Score
describes functional status as a comprehensive 11-point scale
correlating to percentage values ranging from 100% (no evidence of
disease, no symptoms) to 0% (death) [32,33]. Patients with cancer
also completed the European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire C30
(EORTC-QLQ-C30) [34]. The EORTC-QLQ-C30 Quality of Life (QOL)
score reflects how patients rate their overall health and quality of
life. The EORTC-QLQ-C30 daily physical function score expresses
the capacity to perform normal daily activities and varies from 0 to
100, with a high score representing a high level of functioning.2.6. Biochemical analysis
Arterialized-venous blood was put in Li-heparinized or EDTA
tubes (Becton Dickinson Vacutainer system, Franklin Lakes, New
Jersey, USA), immediately put on ice to minimize enzymaticrnover and myofibrillar protein breakdown in advanced cancer are
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plasma. A part of the plasmawas aliquoted into tubes with 0.1 vol of
33% (w/w) trichloroacetic acid or a residue after evaporation of 0.17
vol of 33% (w/w) 5-sulfosalicylic dihydrate, and then vortexed for
denaturation of proteins. Samples were instantly frozen and stored
at 80 C until further analysis. Tracer enrichments [tracer:tracee
ratio (TTR)] and plasma amino acid concentrations were analysed
by LC-MS/MS by isotope dilution as previously reported [14,24]. All
samples were analysed batchwise.
2.7. Calculations of metabolic parameters
Sum of amino acids (sum AA) represents the sum of the con-
centration of all measured amino acids. BCAA is the sum of valine
(Val), leucine (Leu) and isoleucine (Ile). Sum of essential (sum EAA)
amino acids represents the sum of histidine (His), isoleucine (Ile),
Leu, lysine (Lys), Phe, methionine (Met), threonine (Thr), trypto-
phan (Trp) and Val.
Whole body protein synthesis (WBPS), protein breakdown
(WBPB) and net protein breakdown (WBnetPB) were calculated
from the isotope enrichment values of L-Phe-[ring-2H5] and L-Tyr-
[ring-2H2] [35]. Metabolic data were obtained at isotopic steady
state and rates were calculated using the standard steady state
isotope dilution equation [36]. TTR of Phe and Tyr reached an iso-
topic steady state within 2 h of infusion in both groups.
Whole body production (WBP) rates for all other tracers given
with the pulse were measured by non-compartmental analysis
[24]. GraphPad Prism (version 7.0d) was used for non-
compartmental analysis.
The change in TTR over time was fitted [36] and the area under
the curve (AUC) was obtained as previously described [24]. We
calculated the conversion of an amino acid by using the Ra of the
product amino acid and the ratio between the TTR at plateau or
AUC of the TTR from pulse of the product/substrate [24,37,38].
Clearance rate of an amino acid was calculated as Ra/plasma con-
centration of that amino acid [36].
2.8. Statistical analysis
Results are expressed as means ± standard errors (SE). Popula-
tion characteristics and baseline measurements were compared
with the use of the either the unpaired Student's t-test (if datawere
distributed normally) or the ManneWhitney test. Alternatively,
categorical values were compared with the use of the Pearson
ChieSquare test. Bivariate Pearson's correlation analysis was used
to measure the linear correlation between muscle function, mass
and each metabolic variable. The statistical package within
Graphpad Prism (Version 7.0d) and SPSS (version 25) was used for
data analysis. The level of statistical significance was set at P < 0.05.
3. Results
Sixteen patients with solid tumours undergoing chemotherapy
and 16 age- and sex matched healthy controls were studied
(Tables 2 and 3). The average age was 59.3 years in healthy subjects
and 60.1 years in patients with cancer (P ¼ 0.90). In both groups,
44% of the subjects were female. The cancer group formed a het-
erogeneous group that varied in tumour type, treatment regimen
and Karnofsky performance score (Table 3). One patient with can-
cer had stage IIb, 8 had stage III and 7 patients had stage IV disease.
The median time since last chemotherapy was 7 days (range 0e16
days). Five out of 16 patients received chemotherapy and concur-
rent radiotherapy. Fifty per cent of the patients with cancer re-
ported weight loss in the previous month, with an average % of
weight loss of 2.5 ± 2.9%. Pre-cachexia was present in 1 patientPlease cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinicawhen using criteria suggested by Fearon et al. (<5% weight loss,
EORTC QLQ-c30 appetite loss >21.1 and albumin < reference value)
[3]. Two patients were classified as having cachexia based on
Fearon's criteria (5% weight loss and BMI<20 or sarcopenia, based
on: ASMI <7.23 kg/m2 for men; <5.67 kg/m2 for women).
3.1. Body composition and muscle function
Secondary sarcopenia (defined as ASMI <7.23 kg/m2 for men;
<5.67 kg/m2 for women) [39] was present in 38% of the patients
with cancer, while 10 (63%) were abdominally obese (defined as
android/gynoid % FM > 1.0 for men, >0.8 for women) [40],
compared to 19% of healthy subjects with sarcopenia and 11 (69%)
with abdominal obesity. BMI, whole body FFMI, ASMI, and MEP
were not different between the groups, but MIP and leg extension
strength were lower in patients with cancer (P < 0.05). Patients
with cancer tended to have lower handgrip strength than healthy
controls (P¼ 0.06). Energy and protein intake and reported physical
activity level were not different between healthy subjects and pa-
tients with cancer (Table 2).
3.2. Protein metabolism
Post absorptive plasma concentrations of the amino acids Phe,
Tyr, and tau-MetHis were comparable between patients with can-
cer and healthy subjects (Table 4). In contrast, the WBP and clear-
ance of tau-MetHis (Table 4) were significantly higher in patients
with cancer than in healthy controls (0.29 vs.0.20 mmol/kg FFM/h
(þ45%), p ¼ 0.03 and 0.07 vs. 0.04 L/min (þ75%), p < 0.001,
respectively). This indicates a higher whole body myofibrillar pro-
tein breakdown in cancer patients than in healthy controls. Con-
version of phenylalanine to tyrosine (post absorptive WBnetPB)
was not different between patients with cancer and healthy
subjects.
Plasma Leu, BCAA, sum EAA and sum AA concentrations were
comparable between patients with cancer and healthy controls
(Table 4). However, WBP and clearance of leucine were substan-
tially higher in patients with cancer than in healthy controls
(respectively 114.3 vs. 66.3 mmol/kg FFM/h, P < 0.001, and 1.42 vs.
0.78 L/min, p < 0.001) (Table 4).
3.3. Metabolism of the remaining amino acids known to affect
muscle contractility (Tau, Gly, Gln)
The cancer group was characterized by a lower plasma con-
centration value of Tau (29.9 vs. 36.3 mM, P < 0.05), but had com-
parable values to healthy controls for plasma Gly (Table 4). WBP
and clearance of Tau were higher in patients with cancer (respec-
tively 40.6 vs. 25.9 mmol/kgFFM/h, P < 0.001 and 1.41 vs. 0.75 L/min,
P < 0.001), as well as the clearance of Gly (1.26 vs.0.86 L/min,
P ¼ 0.01) (Table 4). Plasma Gln was not different between patients
with cancer and healthy controls, but WBP and clearance were
higher (respectively 491.4 vs. 325.2, P ¼ 0.008 and 1.12 mmol/kg
FFM/h vs. 0.70 L/min, P ¼ 0.001) (Table 4).
3.4. Relationships between muscle mass, function and amino acid
metabolism in patients with cancer
3.4.1. Appendicular skeletal muscle mass
In patients with cancer, reduced ASMI was strongly associated
with muscle weakness as reflected by lower values for handgrip
strength (r: 0.66, P ¼ 0.005), maximum leg extension (r: 0.65,
P ¼ 0.007), and respiratory muscle strength (MEP, r: 0.51, P ¼ 0.04).
ASMI was not significantly correlated to Karnofsky performance
score or EORTC-QLQ-C30 Physical Function and Quality of Life.rnover and myofibrillar protein breakdown in advanced cancer are
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Table 3
Characterization of patients with cancer.
Tumour type n (%)
Esophageal 2 (13)
Gastric/laryngeal 1 (6)
Colorectal 6 (38)
Pancreatic 1 (6)
Lung 3 (19)
Ovarian 3 (19)
Histology n (%)
Adeno 10 (63)
Squamous cell 2 (13)
Small cell 1 (6)
Poorly differentiated 1 (6)
Unknown 2 (13)
Stage n (%)
IIb 1 (6)
III 8 (50)
IV 7 (44)
Laboratory parameters [reference range] mean (SEM)
Hemoglobin (g/dL) [M: 14e18, F: 12e16] 11.6 (0.4)
Albumin (g/dL) [34e47] 38 (1.4)
WCC (x 109/L) [4.8e10.8] 5.4 (0.6)
Physical performance n (%)
Karnofsky performance Score
60 1 (6)
70 2 (13)
80 5 (31)
90 3 (19)
100 1 (12)
Unknown 4 (25)
Physical function (EORTC-QLQ-C30) mean (SEM) 83.3 (16.7)
Appetite loss (EORTC-QLQ-C30) 29.2 (9.6)
Days since diagnosis or recurrence median (range) 57 (10e77)
Days since last chemotherapy administration median (range) 6.9 (0e16)
Chemotherapy regimen n (%)
Cisplatin, Fluorouracil (5-FU), Leucovorin 1 (6)
Carboplatin
þ Etoposide or Paclitaxel or Taxol or Docetaxel 7 (44)
þ Fluorouracil (5-FU), Taxol, Docetaxel 1 (6)
Oxaliplatin, Fluorouracil (5-FU), Leucovorin 3 (19)
þ Bevacizumab 3 (19)
þ Irinotecan 1 (6)
Concurrent radiotherapy n (%) 5 (31)
Unintentional weight loss
% weight loss in previous month mean (SEM) 2.5 (0.8)
5% weight loss in previous month n (%) 6 (37.5)
Number of hospitalisations in last year n (%)
0 5 (31)
1 8 (50)
2 2 (13)
3 e
4 e
5 1 (6)
B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx 5Relationships were found between a low ASMI and amino acid
disturbances as reflected by higher values for the whole body pro-
duction of Gln (r: 0.63, P ¼ 0.02) and Tau (r: 0.56, P ¼ 0.04),
higher clearance rates of Gln (r: 0.67, P ¼ 0.01), lower values for
plasma Phe concentration (r: 0.61, P ¼ 0.02).3.4.2. Muscle strength
Relationships were found between low handgrip strength and
metabolic disturbances in patients with cancer as reflected by
reduced plasma levels of Phe (r: 0.73, P ¼ 0.003; Fig. 1) and Tyr (r:
0.63, P ¼ 0.02) and elevated rates of clearance of Phe (r: 0.66,
P ¼ 0.01), Tyr (r: 0.574, P ¼ 0.03) and Gln (r: 0.65, P ¼ 0.02).
Muscle strength was not significantly correlated to Karnofsky per-
formance score or EORTC-QLQ-C30 Physical Function and Quality of
Life.
Leg muscle weakness was associated with lower plasma con-
centrations of Phe (r: 0.60, P ¼ 0.02) and Tyr (r: 0.61, ¼ 0.01).Please cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinica3.4.3. EORTC-QLQ-C30 physical function and quality of life
Lower reported daily physical function scores in cancer were
associated with lower plasma concentrations of Leu (r: 0.60,
P¼ 0.02), Tau (r: 0.59, P¼ 0.03), EAA (r: 0.55, P¼ 0.041), Sum AA (r:
0.55, P ¼ 0.04) and with higher clearance rates of Leu (r:-0.62,
p ¼ 0.02), Gly (r ¼ 0.59, P ¼ 0.04) and Tau (r: 0.77, P ¼ 0.002)
(Fig. 2).
Lower self-reported quality of life scores were associated with
higher rates of Tau clearance (r: 0.57, P ¼ 0.04).4. Discussion
In the present study, we examined the (protein and amino
acid) metabolic characteristics of a well-described heterogeneous
group of non-cachectic patients with advanced solid tumours
undergoing chemotherapy. We observed no significant weight
loss, muscle wasting or reduced dietary intake, but an evidentrnover and myofibrillar protein breakdown in advanced cancer are
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Table 4
Post-absorptive concentrations in plasma and non-compartmental rate of appearance and clearance of amino acids in healthy controls and patients with cancer.
Mean (SEM) Healthy controls (n ¼ 16) Cancer patients (n ¼ 16) P-value Healthy vs. Cancer
Plasma concentration
Phenylalanine (mmol/L) 42.2 (2.3) 42.5 (2.4) 0.93
Tyrosine (mmol/L) 43.8 (2.7) 45.5 (3.0) 0.68
Tau-Methylhistidine (mmol/L) 5.25 (0.33) 4.73 (0.49) 0.39
Glycine (mmol/L) 190.0 (12.1) 218.8 (31.3) 0.40
Leucine (mmol/L) 97.7 (5.3) 86.9 (7.5) 0.25
Glutamine 453.0 (18.7) 452.9 (21.3) 1.00
Taurine 36.3 (1.6) 29.9 (1.8) 0.02
Sum BCAAs (mmol/L) 334.6 (16.6) 307.0 (25.6) 0.37
Sum EAA (mmol/L) 734.4 (30.8) 688.2 (42.8) 0.38
Sum AA (mmol/L) 2052.3 (64.0) 2037.1 (98.0) 0.90
Rate of appearance
Phenylalanine (mmol/kg ffm/h) 88.6 (3.9) 91.0 (2.7) 0.62
Tyrosine (mmol/kg ffm/h) 58.3 (4.4) 61.9 (1.7) 0.45
Conversion of phenylalanine to tyrosine (mmol/kg ffm/h) 6.8 (0.6) 5.8 (0.3) 0.17
Tau-Methylhistidine (mmol/kg ffm/h) 0.20 (0.02) 0.29 (0.03) 0.03
Glycine (mmol/kg ffm/h) 152.9 (18.5) 215.9 (25.4) 0.05
Leucine (mmol/kg ffm/h) 66.3 (5.7) 114.3 (6.7) <0.001
Glutamine (mmol/kg ffm/h) 325.2 (51.5) 491.4 (32.0) 0.008
Taurine (mmol/kg ffm/h) 25.9 (2.6) 40.1 (2.2) <0.001
Clearance
Phenylalanine (L/min) 2.18 (0.12) 2.27 (0.20) 0.68
Tyrosine (L/min) 1.40 (0.07) 1.43 (0.11) 0.79
Tau-Methylhistidine (L/min) 0.04 (0.00) 0.07 (0.01) <0.001
Glycine (L/min) 0.88 (0.09) 1.26 (0.11) 0.01
Leucine (L/min) 0.78 (0.08) 1.42 (0.23) <0.001
Glutamine (L/min) 0.70 (0.09) 1.13 (0.08) 0.001
Taurine (L/min) 0.75 (0.07) 1.39 (0.08) <0.001
BCAA, branched-chain amino acids (sum of leucine, isoleucine, and valine); EAA, essential amino acids (sum of histidine, isoleucine, leucine, lysine, methionine, phenylalanine,
threonine, tryptophan and valine); AA, amino acids (sum of all amino acids).
Bold values represents P <0.05.
B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx6limb muscle weakness and a consistently increased amino acid
turnover and myofibrillar protein breakdown in patients with
cancer as compared to healthy controls. In addition, we showed
that disturbances in protein metabolism in cancer patients were
associated with appendicular muscle loss, muscle weakness, and
low daily physical function and quality of life scores, showing the
overall impact of metabolic changes on physical health and
wellbeing.4.1. Protein metabolism in relation to muscle mass and function
We found an increased contractile (myofibrillar) protein
breakdown rate compared to age matched control subjects, whileFig. 1. Correlation between handgrip strength and plasma phenylalanine in patients
with cancer.
Please cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinicanet whole body protein catabolism was unchanged. Most of the
total body tau-MetHis pool is present in skeletal muscle, and solely
in myofibrillar protein [41,42]. As proteolysis of myofibrils releases
tau-MetHis that cannot be reused, the WBP of tau-MetHis in
plasma was used to estimate myofibrillar protein breakdown. Our
group recently showed an increased production of tau-MetHis in
healthy older adults compared to younger adults using the same
tracer pulse approach [24], although older adults have comparable
muscle mass, but reduced leg strength. In the present study, pa-
tients with cancer also exhibit limb muscle weakness without
muscle mass loss. This suggests that tau-MetHis WBP relates to the
reduction in strength. The reduction in muscle strength is also
present in patients with non-small cell lung cancer with ECOGFig. 2. Correlation between physical function and taurine clearance in patients with
cancer.
rnover and myofibrillar protein breakdown in advanced cancer are
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B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx 7performance status 0 or 1 (able to carry out normal, or fairly normal
daily activities) andwho had less than 10%weight loss [43]. Ameta-
analysis of studies in breast cancer also showed a lower upper and
lower extremity strength in women who were receiving breast
cancer treatment [44]. Cancer patients are more characterized by
reductions in muscle strength that relate to theWBP of tau-MetHis.
Another explanation of muscle weakness related to metabolic ab-
normalities in cancer is muscle fat infiltration, indicated by muscle
attenuation on CT-images [4].
To measure the production of tau-MetHis by stable tracer
methodology is more accurate to determine myofibrillar protein
breakdown than using plasma concentrations or urine excretion
[41]. Older studies have found a higher excretion of tau-MetHis via
the urine in catabolic conditions [45e47]. Using stable tracers, we
found in tumour-bearing mice a higher production of tau-MetHis
compared to controls [48]. Apart from the production of tau-
MetHis, the production of glutamine has scarcely been investi-
gated in humans with cancer, due to difficulties to measure gluta-
mine WBP with a primed-continuous protocol [49]. Our pulse
methodology allows quantifying the production (rate of appear-
ance) and clearance of glutamine. Our results indicated that pro-
duction and clearance, rather than plasma concentrations, of
glutamine were important markers for metabolic changes in can-
cer, and that the clearance of glutamine negatively correlated to
muscle mass and muscle strength. There were no correlations be-
tween the glutamine and tau-MetHis metabolism. These findings in
patients with cancer have not been published before.
To explore the clinical relevance of abnormal metabolism of
several other amino acids, we investigated relationships between
metabolic markers andmuscle strength, daily physical function and
QOL.We found that lower strength, daily physical function and QOL
scores were associated with higher clearance rates or lower plasma
values of phenylalanine, tyrosine, taurine, leucine or glutamine,
indicating a higher disposal of these amino acids.
Lower levels of daily physical function and QOL were related to
glycine and taurine clearance rates, indicating disposal of these
amino acids relates to patient-reported outcomes. Glycine is a
precursor for metabolites such as creatine and glutathione, and is
involved in muscle synthesis [50]. It has been shown in patients
with cancer that supplemental glycine attenuates muscle wasting
during dieting or fasting, and reduces muscle wasting. Taurine is
abundant inmuscle cells and plays a role in the defence against free
radical-mediated damage after exercise [51], and has a regulatory
effect on ion channels, calcium homeostasis, oxidative stress and
control of membrane excitability [52].
4.2. Weight loss, sarcopenia and obesity
We found noweight loss in contrast to reported in the literature,
despite the advanced stages of our cancer group (mainly stage III
and IV). In a study by Hebuterne and co-workers, weight loss >10%
or underweight were present in 39% of patients with cancer and
depending on tumour sites, this prevalence varied from 1.9% in
prostate cancer to 60.2% in pancreatic cancer [53]. Others docu-
ment malnutrition in patients starting radiotherapy for colorectal,
head and neck, breast, lung or stomach cancer, malnutrition in 31%
and it increased to 43% at the end of radiotherapy [54]. Even at the
first oncology visit, a recently published Italian study observed 9%
of malnutrition and 43% at risk of malnutrition [55]. In the current
study, only 6% of patients undergoing chemotherapy experienced
more than 5% weight loss in 1 month. However, secondary sarco-
penia was present in 37.5%.
What are the reasons for this difference in the prevalence of
weight loss? We found that our patients with cancer did not
experience a high level of anorexia, as they were able to maintainPlease cite this article as: van der Meij BS et al., Increased amino acid tu
associated with muscle weakness and impaired physical function, Clinicasufficient dietary protein and calorie intake. However, we found
that the current patient group had a low level of inflammation, as
most of them were not anaemic and had normal levels of the
negative acute-phase-protein albumin. As we detected several
metabolic disturbances with our tracer methodologies, we hy-
pothesize that many of our patients were pre-cachectic [3], char-
acterized by disturbed metabolism that did not yet lead to any
measurable muscle loss but with significant muscle weakness. This
suggests that treatment that aims to reduce muscle weakness need
to be initiated in the pre-cachexia phase aiming at normalizing the
observed metabolic disturbances.
Obesity is an upcoming phenomenon in our society and as a
result, rates of obesity in the cancer population show the same trend
in the increased prevalence of obesity as the general population [20].
Of patients with cancer in the current study, 50% were overweight or
obese, which is comparable with the literature [56]. None were
reporting any fluid retention that could cause overestimation of BMI
and presence of obesity. As obesity increases the risk of muscle
weakness, loss and treatment toxicity [57], these pre-cachectic pa-
tients require nutrition assessment and appropriate nutrition sup-
port, just as much as patients who have cachexia or underweight.
Our data showing elevated levels of protein turnover, myofi-
brillar protein breakdown and muscle wasting correspond with
other metabolic studies in small groups of cancer patients
[19,48,58] and therefore we think that our study provides useful
information about protein metabolism in patients undergoing
chemotherapy. We showed that even in patients who would not be
classified as pre-cachectic or cachectic, the body responds to the
disease and the treatment, resulting in a significantly higher pro-
tein turnover and myofibrillar protein breakdown and many de-
teriorations in the production and clearance rate of amino acids,
which were related to muscle function, physical function and
quality of life. These novel findings can be used for clinicians to be
aware of metabolic changes that do not yet translate into clinical
impairments. The higher protein turnover and alterations in amino
acid metabolism in non-cachectic patients with cancer indicates a
probable higher demand for dietary protein. An increased protein
intake has been shown to promote muscle protein anabolism [59]
and is recommended by the ESPEN guidelines for patients with
cancer [60]. We know that many patients potentially can have a
problem reaching adequate and optimal protein intakes. Future
research should look at metabolic and functional changes in large
and heterogeneous groups of cancer, and ideally investigate effects
of different chemotherapy regimens on protein metabolism.
4.3. Limitations
A limitation of this study is that the group is small and hetero-
geneous. The group might not be representative for all patients
with cancer undergoing chemotherapy, as we enrolled 6 different
types of cancer with small numbers representing each cancer type.
Our data probably represent metabolic changes that occur in many
patients with cancer undergoing chemotherapy. Some preclinical
studies indicate effects of certain chemotherapy drugs on muscle
metabolism [8,9], like handgrip strength [6,7] and quadriceps
strength [6]. In the current study, we are measuring heterogeneous
patients with cancer undergoing different types of chemotherapy
and cannot isolate the effect of chemotherapy. Also, as patients
with progressive disease who were unwell were not able to
participate in this full day metabolic study, which could have
caused selection bias and could explain the relatively low amount
of muscle wasting andmuscle weakness, and relatively high quality
of life in this study.
In conclusion, this study shows that pre-cachectic patients with
advanced cancer undergoing chemotherapy with reduced musclernover and myofibrillar protein breakdown in advanced cancer are
l Nutrition, https://doi.org/10.1016/j.clnu.2018.10.022
B.S. van der Meij et al. / Clinical Nutrition xxx (xxxx) xxx8strength and unchanged muscle mass and normal reported phys-
ical activity have already an increased amino acid turnover and
myofibrillar protein breakdown that relates to their reducedmuscle
strength and physical function.
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